StrengthTalking point
Profit outpacing revenue
Profit grew 148.4% while revenue grew 22.7%, so the company kept more of each rupee of revenue as profit.
Importance 72 / 95 · growth
Laurus Labs Limited · Research view
Laurus Labs Limited
NSE: LAURUSLABSBSE: 540222ISIN INE947Q01028Face value ₹2standalone
₹1,989
+0.37% · 2026-10-01 · 52-wk ₹854–₹2,035
Financials to FY2026 · 8 years of history · prices to 2026-10-01consolidatedstandalone
Section 02 · Synthesis
What stands out?
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
StrengthConcernWatchContext
WatchTalking point
Stock has run ahead of the business
Over 5 years the stock returned 26.3% a year while profit shrank 2.0% a year.
Importance 61 / 95 · business vs stock
WatchTalking point
Volatile earnings
Profit has swung sharply over 7 years (from ₹94 to ₹984) — one year is a weak guide to the earnings power.
Importance 58 / 95 · growth
Context
Higher P/E than peers
Trades at 98.46× earnings — 172% above the pharmaceuticals median of 36.26×.
Importance 56 / 95 · valuation
Section 03 · The company
Who is this company?
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
- Market cap
- ₹1.07 L cr
- FY2026 revenue
- ₹6,089 cr
- FY2026 net profit
- ₹740 cr
- Net worth
- ₹5,252 cr
- Total debt
- ₹1,999 cr
- EPS (basic)
- ₹13.72
- Listed
- NSE · BSE
- Reporting
- Ind-ASApr–Mar
Peer set used on this page: 12 pharmaceuticals.
Section 04 · Business performance
Is the business growing?
RevenueNet profit
Strength
Profit grew 148.4% while revenue grew 22.7%, so the company kept more of each rupee of revenue as profit.
Rule PROFIT_FASTER_THAN_REVENUE
- Revenue growth per year
- +15.4%over 7 years
- Revenue growth
- +16.7%vs last year
- Net profit growth
- +94.7%vs last year
- Change in net profit since FY19
- +680%
Profit has swung sharply over 7 years (from ₹94 to ₹984) — one year is a weak guide to the earnings power.
Over 7 years profit compounded at 37.9% a year while revenue compounded at 16.8% a year — though FY2021 saw a one-off step-change of 285% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Revenue compounded at 16.8% a year over 7 years (₹2,292 → ₹6,813) — though FY2021 saw a one-off step-change of 70% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Net profit rose 148.4% to ₹890 — but FY2025 was a depressed ₹358 (vs a ~₹524 historical norm), so this is a recovery. Profit has compounded 37.9% a year over 7 years.
Revenue grew 22.7% year on year (FY2025 → FY2026).
Section 05 · Recent activity
What changed recently?
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Strength
Q1 FY27 net profit was ₹362 cr, up 123.9% from ₹162 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Strength
Q1 FY27 revenue was ₹2,026 cr, up 29.1% from ₹1,570 cr in Q1 FY26 a year earlier.
Rule QTR_REVENUE_GROWTH_YOY
Strength
Q1 FY27 net profit grew 123.9% while revenue grew 29.1% vs the same quarter last year — a gap of 94.8 percentage points.
Rule QTR_PROFIT_VS_REVENUE_GROWTH
A. Quarterly results
RevenueNet profit
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q2 FY25 | 1,224 | — | 20 | — | 1.6% |
| Q3 FY25 | 1,415 | +18.4% | 93 | +298.2% | 6.6% |
| Q4 FY25 | 1,720 | +19.5% | 233 | +210.3% | 13.5% |
| Q1 FY26 | 1,570 | +31.4% | 162 | +1175.1% | 10.3% |
| Q2 FY26 | 1,653 | +35.1% | 194 | +874.9% | 11.8% |
| Q3 FY26 | 1,778 | +25.7% | 252 | +171.0% | 14.2% |
| Q4 FY26 | 1,812 | +5.3% | 282 | +21.2% | 15.6% |
| Q1 FY27 | 2,026 | +29.1% | 362 | +123.9% | 17.9% |
B. TTM snapshot
Trailing twelve months to 30 Jun 2026 · sum of the last 4 contiguous quarters
- Revenue
- ₹7,270 crTTM
- EBITDA
- ₹2,088 crTTM
- EBIT
- ₹1,600 crTTM
- PBT
- ₹1,439 crTTM
- Net profit
- ₹1,091 crTTM
C. Corporate actions
8 May 2026DividendInterim Dividend - Rs. - 1.2000 — ₹1.20/share
31 Oct 2025DividendInterim Dividend - Rs. - 0.8000 — ₹0.80/share
9 May 2025DividendInterim Dividend - Rs. - 0.8000 — ₹0.80/share
6 Nov 2024DividendInterim Dividend - Rs. - 0.4000 — ₹0.40/share
8 May 2024DividendInterim Dividend - Rs. - 0.4000 — ₹0.40/share
2 Nov 2023DividendInterim Dividend - Rs. - 0.4000 — ₹0.40/share
10 May 2023DividendInterim Dividend - Rs. - 1.2000 — ₹1.20/share
3 Nov 2022DividendInterim Dividend - Rs. - 0.8000 — ₹0.80/share
10 May 2022DividendInterim Dividend - Rs. - 1.2000 — ₹1.20/share
17 Nov 2021DividendInterim Dividend - Rs. - 0.8000 — ₹0.80/share
11 May 2021DividendInterim Dividend - Rs. - 0.8000 — ₹0.80/share
8 Feb 2021DividendInterim Dividend - Rs. - 0.4000 — ₹0.40/share
10 Nov 2020DividendInterim Dividend - Rs. - 0.8000 — ₹0.80/share
29 Sept 2020Stock splitStock Split From Rs.10/- to Rs.2/- — 10:2
1 Jul 2020DividendFinal Dividend - Rs. - 1.0000 — ₹1.00/share
23 Mar 2020DividendInterim Dividend - Rs. - 1.5000 — ₹1.50/share
3 Jul 2019DividendDividend - Rs. - 1.5000 — ₹1.50/share
28 Jun 2018DividendDividend - Rs. - 1.5000 — ₹1.50/share
6 Jul 2017DividendDividend - Rs. - 1.5000 — ₹1.50/share
Section 06 · Business performance
Is it becoming more profitable?
EBITDA marginNet margin
Strength
EBITDA margin improved from 20.4% to 26.9% of revenue.
Rule MARGIN_EXPANDED_YOY
- EBITDA margin now
- 24.9%
- 8-year range
- 16.4–32.2%
- ROE FY2026
- 15.1%
- ROCE FY2026
- 16.1%
ROE rose from 8.2% to 17.7% — but FY2025 was a depressed year, so this is a rebound rather than a step-up.
EBITDA margin has ranged from 15.9% to 32.7% over 7 years and sits at 26.9% now.
Section 07 · Financial health
Is financial health improving?
Net worth (shareholders' funds)
Strength
Operating cash flow has matched or exceeded reported profit in 5 of the last 6 profit-making years (latest 1.82×).
Rule CFO_CONSISTENTLY_EXCEEDS_PAT
Operating cash flowNet profit
- Total debt
- ₹1,999 cr
- Operating cash flow ÷ net profit
- 1.87×FY2026
- Free cash flow
- ₹677 cr
- Current ratio
- 1.34×
Net worth compounded at 19.5% a year over 7 years (₹1,558 → ₹5,431) — though FY2021 saw a one-off step-change of 47% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Free cash flow has been positive in 5 of the last 6 years.
Section 08 · Relative position
How does it compare with peers?
Ranked against 12 pharmaceuticals (FY2026, consolidated).
Revenue growth
LAURUSLABS · 3rd of 12 · set median 14.8%
EBITDA margin
LAURUSLABS · 8th of 12 · set median 28.7%
Return on equity
LAURUSLABS · 3rd of 12 · set median 14.4%
P/E ratio
LAURUSLABS · 11th of 12 · set median 36.3×
Context
Trades at 98.46× earnings — 172% above the pharmaceuticals median of 36.26×.
Rule PE_ABOVE_PEERS
- P / E
- 98.5×TTM to Jun 26
- P / B
- 19.8×latest book
- P / S
- 14.8×TTM sales
- Earnings yield
- 1.0%TTM to Jun 26
On the trailing twelve months. Last full year: P/E 120.6× · P/S 15.6× · ROE 17.7%. TTM and full-year profit differ by more than 15% — a one-off in a recent quarter is moving the trailing figure; weigh it against the full year.
Section 09 · The stock
How has the stock performed?
Watch
Over 5 years the stock returned 26.3% a year while profit shrank 2.0% a year.
Rule STOCK_RAN_AHEAD
- 1-year return
- +128.1%
- 3-year return
- +403.0%
- 5-year return
- +221.2%
- From 52-wk high
- −2.3%
Section 10 · Technical data
What does the technical data say?
Price-action indicators as of 2026-10-01. Secondary to the fundamentals above — included for timing context, not as a signal.
- vs 50-day avg
- Above₹1,874
- vs 200-day avg
- Above₹1,354
- RSI (14)
- 59.0neutral
- MACD histogram
- -5.7
- From 52-wk high
- −2.3%
- From 52-wk low
- +132.9%
- 30-day volatility
- 25.9%ann.
- 6-month return
- +100.4%
Section 11 · Open questions
What should I investigate further?
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
- WatchStock has run ahead of the businessOver 5 years the stock returned 26.3% a year while profit shrank 2.0% a year.STOCK_RAN_AHEAD · conviction 61
- WatchVolatile earningsProfit has swung sharply over 7 years (from ₹94 to ₹984) — one year is a weak guide to the earnings power.EARNINGS_VOLATILE · conviction 58
- Cash-flow-statement facts are unavailable for FY2019, FY2020 — those filings predate SEBI's Cash Flow Statement disclosure requirement. All other loaded years carry full P&L, balance sheet and cash-flow data.
Section 12 · Reference
The numbers
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,236 | 2,797 | 4,769 | 4,707 | 5,773 | 4,812 | 5,217 | 6,089 |
| Total income | 2,252 | 2,803 | 4,796 | 4,729 | 5,789 | 4,860 | 5,317 | 6,167 |
| EBITDA | 368 | 576 | 1,537 | 1,307 | 1,498 | 797 | 1,045 | 1,516 |
| Profit before tax | 121 | 304 | 1,275 | 975 | 1,051 | 301 | 504 | 994 |
| Net profit | 95 | 267 | 956 | 750 | 760 | 224 | 380 | 740 |
| EPS (₹) | 8.9 | 25.0 | 17.9 | 14.0 | 14.1 | 4.2 | 7.1 | 13.7 |
| Net worth | 1,591 | 1,816 | 2,712 | 3,388 | 4,057 | 4,207 | 4,564 | 5,252 |
| Total debt | 916 | 927 | 1,260 | 1,620 | 1,681 | 2,049 | 2,325 | 1,999 |
| Operating cash flow | — | — | 694 | 823 | 882 | 659 | 540 | 1,385 |
| Free cash flow | — | — | 98 | 62 | 141 | 293 | 258 | 677 |
| Ratio | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Growth | ||||||||
| Revenue growth YoY | — | 25.1 | 70.5 | -1.3 | 22.7 | -16.6 | 8.4 | 16.7 |
| Profit growth YoY | — | 181.1 | 258.0 | -21.5 | 1.4 | -70.6 | 70.0 | 94.7 |
| Profitability | ||||||||
| EBITDA margin % | 16.4 | 20.6 | 32.2 | 27.8 | 25.9 | 16.6 | 20.0 | 24.9 |
| Net margin % | 4.2 | 9.5 | 19.9 | 15.9 | 13.1 | 4.6 | 7.2 | 12.0 |
| Return on equity % | 6.0 | 15.7 | 42.2 | 24.6 | 20.4 | 5.4 | 8.7 | 15.1 |
| Return on capital % | 8.3 | 14.9 | 39.9 | 23.9 | 22.3 | 7.5 | 10.4 | 16.1 |
| Leverage & cash | ||||||||
| Debt to equity | 0.58 | 0.51 | 0.46 | 0.48 | 0.41 | 0.49 | 0.51 | 0.38 |
| Cash flow ÷ profit | — | — | 0.73 | 1.10 | 1.16 | 2.94 | 1.42 | 1.87 |
| Current ratio | 1.04 | 1.09 | 1.29 | 1.32 | 1.51 | 1.29 | 1.27 | 1.34 |